Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice

Human Molecular Genetics

Volumn 23, Issue 15, 2014, Pages 3943-3957

  Xu, You Hai ^a,b   Xu, Kui ^a   Sun, Ying ^a,b   Liou, Benjamin ^a   Quinn, Brian ^a   Li, Rong Hua ^a,b   Xue, Ling ^c   Zhang, Wujuan ^a   Setchell, Kenneth D R ^a,b   Witte, David ^a,b   Grabowski, Gregory A ^a,b,d  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d Synageva BioPharma Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA GLUCOSIDASE; GLUCOSYLCERAMIDE; GLUCOSYLSPHINGOSINE; GLYCOSPHINGOLIPID; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; UBIQUITIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; CONDURITOL EPOXIDE; ENZYME INHIBITOR; INOSITOL; LAMP1 PROTEIN, MOUSE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; MAP1LC3 PROTEIN, MOUSE; MICROTUBULE ASSOCIATED PROTEIN; MITOCHONDRIAL OUTER MEMBRANE PROTEIN 35-KDA, MOUSE; MITOCHONDRIAL PROTEIN; PROSTAGLANDIN SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOLYSOSOME; BRAIN CELL CULTURE; BRAIN CORTEX; CELL COMPARTMENTALIZATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; GAUCHER DISEASE; HIPPOCAMPUS; INTRACELLULAR SPACE; MITOCHONDRION; MOUSE; NEWBORN; NONHUMAN; OXYGEN CONSUMPTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PUTAMEN; SIGNAL TRANSDUCTION; STRATUM CORNEUM; SUBSTANTIA NIGRA; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CORPUS STRIATUM; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NERVE CELL; PATHOLOGY; PROTEINOSIS;

ALPHA-SYNUCLEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BETA-GLUCOSIDASE; CELLS, CULTURED; CEREBRAL CORTEX; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GAUCHER DISEASE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; INOSITOL; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NEURONS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN AGGREGATION, PATHOLOGICAL; SUBSTANTIA NIGRA;

EID: 84903984646     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu105     Document Type: Article

References (95)

1. Grabowski, G.A., Petsko, G.A. and Kolodny, E.H. (2010) Gaucher disease. In: Valle, D., Beaudet, A.L., Vogelstein, B., Kinzler, K.W., Antonarakis, S.E. and Ballabio, A. (eds), Metabolic and Molecular Bases of InheritedDisease (OMMBID Mark II). New York: McGraw-Hill Companies, Inc.
2. Sibille, A., Eng, C.M., Kim, S.J., Pastores, G. and Grabowski, G.A. (1993) Phenotype/genotype correlations in Gaucher disease type I, clinical andtherapeutic implications. Am. J. Hum. Genet., 52, 1094-1101.
3. Zimran, A., Kay, A., Gelbart, T., Garver, P., Thurston, D., Saven, A. andBeutler, E. (1992) Gaucher disease. Clinical, laboratory, radiologic, andgenetic features of 53 patients. Medicine, 71, 337-353.
4. Grabowski, G.A. (2008) Phenotype, diagnosis, and treatment of Gaucher'sdisease. Lancet, 372, 1263-1271.
5. Hirsch, E.C. and Hunot, S. (2009) Neuroinflammation in Parkinson'sdisease: a target for neuroprotection? Lancet Neurol., 8, 382-397.
6. Sun, Y., Liou, B., Ran, H., Skelton, M.R., Williams, M.T., Vorhees, C.V., Kitatani, K., Hannun, Y.A., Witte, D.P., Xu, Y.H. et al. (2010) Neuronopathic Gaucher disease in the mouse: viable combined selectivesaposin C deficiency and mutant glucocerebrosidase (V394L) mice withglucosylsphingosine and glucosylceramide accumulation and progressiveneurological deficits. Hum. Mol. Genet., 19, 1088-1097.
7. Sun, Y., Ran, H., Zamzow, M., Kitatani, K., Skelton, M.R., Williams, M.T., Vorhees, C.V., Witte, D.P., Hannun, Y.A. and Grabowski, G.A. (2010) Specific saposin C deficiency: CNS impairment and acid beta-glucosidaseeffects in the mouse. Hum. Mol. Genet., 19, 634-647.
8. Wong, K., Sidransky, E., Verma, A., Mixon, T., Sandberg, G.D., Wakefield, L.K., Morrison, A., Lwin, A., Colegial, C., Allman, J.M. et al. (2004) Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Metab., 82, 192-207.
9. Xu, Y.H., Sun, Y., Ran, H., Quinn, B., Witte, D. and Grabowski, G.A. (2011) Accumulation and distribution of alpha-synuclein and ubiquitin in the CNSof Gaucher disease mouse models. Mol. Genet. Metab., 102, 436-447.
10. Jellinger, K.A. (2008) Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener. Dis., 5, 118-121.
11. Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L. and Beyreuther, K. (1985)Amyloidplaque core protein in Alzheimer diseaseand Down syndrome. Proc. Natl. Acad. Sci.USA, 82, 4245-4249.
12. Norremolle, A., Riess, O., Epplen, J.T., Fenger, K., Hasholt, L. andSorensen, S.A. (1993) Trinucleotide repeat elongation in the Huntingtongene in Huntington disease patients from 71 Danish families. Hum. Mol. Genet., 2, 1475-1476.
13. Suzuki, K., Iseki, E., Katsuse, O., Yamaguchi, A., Katsuyama, K., Aoki, I., Yamanaka, S. and Kosaka, K. (2003) Neuronal accumulation of alpha-andbeta-synucleins in the brain of a GM2 gangliosidosis mouse model. Neuroreport., 14, 551-554.
14. Auer, I.A., Schmidt, M.L., Lee, V.M., Curry, B., Suzuki, K., Shin, R.W., Pentchev, P.G., Carstea, E.D. and Trojanowski, J.Q. (1995) Paired helicalfilament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtauin Alzheimer's disease. Acta Neuropathol., 90, 547-551.
15. Goker-Alpan, O., Giasson, B.I., Eblan, M.J., Nguyen, J., Hurtig, H.I., Lee, V.M., Trojanowski, J.Q. and Sidransky, E. (2006) Glucocerebrosidasemutations are an important risk factor for Lewy body disorders. Neurology, 67, 908-910.
16. Tayebi, N., Walker, J., Stubblefield, B., Orvisky, E., LaMarca, M.E., Wong, K., Rosenbaum, H., Schiffmann, R., Bembi, B. and Sidransky, E. (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidasedeficiency contribute to a vulnerability to parkinsonism? Mol. Genet. Metab., 79, 104-109.
17. Mazzulli, J.R., Xu, Y.H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A., Sidransky, E., Grabowski, G.A. and Krainc, D. (2011) Gaucher diseaseglucocerebrosidase and alpha-synuclein form a bidirectional pathogenicloop in synucleinopathies. Cell, 146, 37-52.
18. Cullen, V., Sardi, S.P., Ng, J., Xu, Y.H., Sun, Y., Tomlinson, J.J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J. et al. (2011) Acid beta-glucosidase mutantslinked to Gaucher disease, Parkinson disease, and Lewy body dementia alteralpha-synuclein processing. Ann. Neurol., 69, 940-953.
19. Sardi, S.P., Clarke, J., Kinnecom, C., Tamsett, T.J., Li, L., Stanek, L.M., Passini, M.A., Grabowski, G.A., Schlossmacher, M.G., Sidman, R.L. et al. (2011) CNS expression of glucocerebrosidase corrects alpha-synucleinpathology and memory in a mouse model of Gaucher-relatedsynucleinopathy. Proc. Natl. Acad. Sci. USA, 108, 12101-12106.
20. Osellame, L.D., Rahim, A.A., Hargreaves, I.P., Gegg, M.E., Richard-Londt, A., Brandner, S., Waddington, S.N., Schapira, A.H. and Duchen, M.R. (2013) Mitochondria and quality control defects in a mouse model ofGaucher disease-links to Parkinson's disease. Cell Metab., 17, 941-953.
21. Trojanowski, J.Q. and Lee, V.M. (2002) Parkinson's disease and relatedsynucleinopathies are a new class of nervous system amyloidoses. Neurotoxicology, 23, 457-460.
22. Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B. and Zimran, A. (1996) Occurrence of Parkinson'ssyndrome in type I Gaucher disease. QJM, 89, 691-694.
23. Sidransky, E. (2005) Gaucher disease and parkinsonism. Mol. Genet. Metab., 84, 302-304.
24. Goldin, E. (2010) Gaucher disease and parkinsonism, a molecular linktheory. Mol. Genet. Metab., 101, 307-310.
25. Nalls, M.A., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I.G., Chinnery, P.F., Morris, C.M., Theuns, J., Crosiers, D., Cras, P. et al. (2013)Amulticenter study of glucocerebrosidase mutations in dementia with lewybodies. JAMA Neurol., 70, 727-735.
26. Sun, Y., Quinn, B., Witte, D.P. and Grabowski, G.A. (2005) Gaucher diseasemouse models: point mutations at the acid beta-glucosidase locus combinedwith low-level prosaposin expression lead to disease variants. J. Lipid Res., 46, 2102-2113.
27. Velayati, A., Yu, W.H. and Sidransky, E. (2010) The role ofglucocerebrosidase mutations in Parkinson disease and Lewy bodydisorders. Curr. Neurol. Neurosci. Rep., 10, 190-198.
28. Lashley, T., Holton, J.L., Gray, E., Kirkham, K., O'Sullivan, S.S., Hilbig, A., Wood, N.W., Lees, A.J. and Revesz, T. (2008) Cortical alpha-synuclein loadis associated with amyloid-beta plaque burden in a subset of Parkinson'sdisease patients. Acta Neuropathol., 115, 417-425.
29. Pletnikova, O., West, N., Lee, M.K., Rudow, G.L., Skolasky, R.L., Dawson, T.M., Marsh, L. and Troncoso, J.C. (2005) Abeta deposition is associatedwith enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol. Aging, 26, 1183-1192.
30. Devi, L., Prabhu, B.M., Galati, D.F., Avadhani, N.G. andAnandatheerthavarada, H.K. (2006) Accumulation of amyloid precursorprotein in the mitochondrial import channels of human Alzheimer'sdisease brain is associated with mitochondrial dysfunction. J. Neurosci., 26, 9057-9068.
31. Lustbader, J.W., Cirilli, M., Lin, C., Xu, H.W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M. et al. (2004)ABADdirectlylinks Abeta to mitochondrial toxicity in Alzheimer's disease. Science, 304, 448-452.
32. Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J.W., Xu, H.W., Stern, D., McKhann, G. and Yan, S.D. (2005) MitochondrialAbeta: a potential focal point for neuronal metabolic dysfunction inAlzheimer's disease. FASEB J., 19, 2040-2041.
33. Crouch, P.J., Blake, R., Duce, J.A., Ciccotosto, G.D., Li, Q.X., Barnham, K.J., Curtain, C.C., Cherny, R.A., Cappai, R., Dyrks, T. et al. (2005) Copper-dependent inhibition of human cytochrome c oxidase by a dimericconformer of amyloid-beta1-42. J. Neurosci., 25, 672-679.
34. Manczak, M., Anekonda, T.S., Henson, E., Park, B.S., Quinn, J. and Reddy, P.H. (2006) Mitochondria are a direct site of A beta accumulation inAlzheimer's disease neurons: implications for free radical generation andoxidativedamage in disease progression. Hum.Mol. Genet., 15, 1437-1449.
35. Anandatheerthavarada, H.K. and Devi, L. (2007) Amyloid precursor proteinand mitochondrial dysfunction in Alzheimer's disease. Neuroscientist, 13, 626-638.
36. Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M. and Mucke, L. (2001) beta-amyloid peptides enhancealpha-synuclein accumulation and neuronal deficits in a transgenic mousemodel linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. USA, 98, 12245-12250.
37. Mandal, P.K., Pettegrew, J.W., Masliah, E., Hamilton, R.L. and Mandal, R. (2006) Interaction between Abeta peptide and alpha synuclein: molecularmechanisms in overlapping pathology of Alzheimer's and Parkinson's indementia with Lewy body disease. Neurochem. Res., 31, 1153-1162.
38. Marsh, S.E. and Blurton-Jones, M. (2012) Examining the mechanisms thatlink beta-amyloid and alpha-synuclein pathologies. Alzheimers Res. Ther., 4, 11.
39. Sun, Y., Qi, X., Witte, D.P., Ponce, E., Kondoh, K., Quinn, B. andGrabowski, G.A. (2002) Prosaposin: threshold rescue and analysis of the "neuritogenic" region in transgenic mice. Mol. Genet. Metab., 76, 271-286.
40. Xu, Y.H., Quinn, B., Witte, D. and Grabowski, G.A. (2003) Viable mousemodels of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am. J. Pathol., 163, 2093-2101.
41. Albert-Weissenberger, C., Stetter, C., Meuth, S.G., Gobel, K., Bader, M., Siren, A.L. and Kleinschnitz, C. (2012) Blocking of bradykinin receptor B1 protects from focal closed head injury in mice by reducing axonal damageand astroglia activation. J. Cereb. Blood Flow Metab., 32, 1747-1756.
42. Svetlov, S.I., Prima, V., Glushakova, O., Svetlov, A., Kirk, D.R., Gutierrez, H., Serebruany, V.L., Curley, K.C., Wang, K.K. and Hayes, R.L. (2012) Neuro-glial and systemic mechanisms of pathological responses in ratmodels of primary blast overpressure compared to "composite" blast. Front. Neurol., 3, 15.
43. Finkbeiner, S., Cuervo, A.M., Morimoto, R.I. and Muchowski, P.J. (2006) Disease-modifying pathways in neurodegeneration. J. Neurosci., 26, 10349-10357.
44. Komatsu,M. and Ichimura, Y. (2010) Physiological significance of selectivedegradation of p62 by autophagy. FEBS Lett., 584, 1374-1378.
45. Bender, A., Desplats, P., Spencer, B., Rockenstein, E., Adame, A., Elstner, M., Laub, C., Mueller, S., Koob, A.O., Mante, M. et al. (2013) TOM40 mediates mitochondrial dysfunction induced by alpha-synucleinaccumulation in Parkinson's disease. PLoS One, 8, e62277.
46. Dickson, D.W., Ruan, D., Crystal, H., Mark, M.H., Davies, P., Kress, Y. andYen, S.H. (1991) Hippocampal degeneration differentiates diffuse Lewybody disease (DLBD) from Alzheimer's disease: light and electronmicroscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology, 41, 1402-1409.
47. Lippa, C.F., Fujiwara, H., Mann, D.M., Giasson, B., Baba, M., Schmidt, M.L., Nee, L.E., O'Connell, B., Pollen, D.A., St George-Hyslop, P. et al. (1998) Lewy bodies contain altered alpha-synuclein in brains of manyfamilial Alzheimer's disease patients with mutations in presenilin andamyloid precursor protein genes. Am. J. Pathol., 153, 1365-1370.
48. Lippa, C.F., Schmidt, M.L., Lee, V.M. and Trojanowski, J.Q. (1999) Antibodies to alpha-synuclein detect Lewy bodies in many Down'ssyndrome brains with Alzheimer's disease. Ann. Neurol., 45, 353-357.
49. Premkumar, L., Sawkar, A.R., Boldin-Adamsky, S., Toker, L., Silman, I., Kelly, J.W., Futerman, A.H. and Sussman, J.L. (2005) X-ray structure ofhuman acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease. J. Biol. Chem., 280, 23815-23819.
50. Broe, M., Shepherd, C.E., Mann, D.M., Milward, E.A., Gai, W.P., Thiel, E. and Halliday, G.M. (2005) Insoluble alpha-synuclein in Alzheimer's diseasewithout Lewy body formation. Neurotoxic. Res., 7, 69-76.
51. Mastaglia, F.L., Johnsen, R.D., Byrnes, M.L. and Kakulas, B.A. (2003) Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson'sdisease. Mov. Disord., 18, 81-86.
52. Thorns, V., Mallory, M., Hansen, L. and Masliah, E. (1997) Alterations inglutamate receptor 2/3 subunits and amyloid precursor protein expressionduring the course of Alzheimer's disease and Lewy body variant. ActaNeuropathol., 94, 539-548.
53. Delacourte, A., Sergeant, N., Champain, D., Wattez, A., Maurage, C.A., Lebert, F., Pasquier, F. and David, J.P. (2002) Nonoverlapping butsynergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology, 59, 398-407.
54. Lee, E.N., Cho, H.J., Lee, C.H., Lee, D., Chung, K.C. and Paik, S.R. (2004) Phthalocyanine tetrasulfonates affect the amyloid formation andcytotoxicity of alpha-synuclein. Biochemistry, 43, 3704-3715.
55. Anandatheerthavarada, H.K., Biswas, G., Robin, M.A. and Avadhani, N.G. (2003) Mitochondrial targeting and a novel transmembrane arrest ofAlzheimer's amyloid precursor protein impairs mitochondrial function inneuronal cells. J. Cell Biol., 161, 41-54.
56. Devi, L., Raghavendran, V., Prabhu, B.M., Avadhani, N.G. andAnandatheerthavarada, H.K. (2008) Mitochondrial import andaccumulation of alpha-synuclein impair complex I in human dopaminergicneuronal cultures and Parkinson disease brain. J. Biol. Chem., 283, 9089-9100.
57. Mattson, M.P., Pedersen, W.A., Duan, W., Culmsee, C. and Camandola, S. (1999) Cellular and molecular mechanisms underlying perturbed energymetabolism and neuronal degeneration in Alzheimer's and Parkinson'sdiseases. Ann. N. Y. Acad. Sci., 893, 154-175.
58. Eckert, A., Steiner, B., Marques, C., Leutz, S., Romig, H., Haass, C. andMuller, W.E. (2001) Elevated vulnerability to oxidative stress-induced celldeath and activation of caspase-3 by the Swedish amyloid precursor proteinmutation. J. Neurosci. Res., 64, 183-192.
59. Marques, C.A., Keil, U., Bonert, A., Steiner, B., Haass, C., Muller, W.E. andEckert, A. (2003) Neurotoxic mechanisms caused by the Alzheimer'sdisease-linked Swedish amyloid precursor protein mutation: oxidativestress, caspases, and the JNK pathway. J. Biol. Chem., 278, 28294-28302.
60. Trushina, E. and McMurray, C.T. (2007) Oxidative stress and mitochondrialdysfunction in neurodegenerative diseases. Neuroscience, 145, 1233-1248.
61. Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R.L., Atwood, C.S., Johnson, A.B., Kress, Y., Vinters, H.V., Tabaton, M. et al. (2001) Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci., 21, 3017-3023.
62. Poon, H.F., Frasier, M., Shreve, N., Calabrese, V., Wolozin, B. andButterfield, D.A. (2005) Mitochondrial associated metabolic proteins areselectively oxidized in A30P alpha-synuclein transgenic mice-a model offamilial Parkinson's disease. Neurobiol. Dis., 18, 492-498.
63. Nilsson, O. and Svennerholm, L. (1982) Accumulation of glucosylceramideand glucosylsphingosine (psychosine) in cerebrum and cerebellum ininfantile and juvenile Gaucher disease. J. Neurochem., 39, 709-718.
64. Igisu, H., Hamasaki, N., Ito, A. and Ou,W.(1988) Inhibition of cytochrome coxidase and hemolysis caused by lysosphingolipids. Lipids, 23, 345-348.
65. Ollinger, K. and Brunk, U.T. (1995) Cellular injury induced by oxidativestress is mediated through lysosomal damage. Free Radic. Biol. Med., 19, 565-574.
66. Pavlov, P.F., Hansson Petersen, C., Glaser, E. and Ankarcrona, M. (2009) Mitochondrial accumulation of APP and Abeta: significance for Alzheimerdisease pathogenesis. J. Cell Mol. Med., 13, 4137-4145.
67. Kish, S.J., Bergeron, C., Rajput, A., Dozic, S., Mastrogiacomo, F., Chang, L.J., Wilson, J.M., DiStefano, L.M. and Nobrega, J.N. (1992) Braincytochrome oxidase in Alzheimer's disease. J. Neurochem., 59, 776-779.
68. Cardoso, S.M., Proenca, M.T., Santos, S., Santana, I. and Oliveira, C.R. (2004) Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol. Aging, 25, 105-110.
69. Borghammer, P., Cumming, P., Ostergaard, K., Gjedde, A., Rodell, A., Bailey, C.J. and Vafaee, M.S. (2012) Cerebral oxygen metabolism inpatients with early Parkinson's disease. J. Neurol. Sci., 313, 123-128.
70. Zhu, X., Smith, M.A., Perry, G. and Aliev, G. (2004) Mitochondrial failuresin Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen., 19, 345-352.
71. Nixon, R.A., Wegiel, J., Kumar, A., Yu, W.H., Peterhoff, C., Cataldo, A. andCuervo, A.M. (2005) Extensive involvement of autophagy in Alzheimerdisease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol., 64, 113-122.
72. Boland, B., Kumar, A., Lee, S., Platt, F.M., Wegiel, J., Yu, W.H. and Nixon, R.A. (2008) Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J. Neurosci., 28, 6926-6937.
73. Jaeger, P.A., Pickford, F., Sun, C.H., Lucin, K.M., Masliah, E. andWyss-Coray, T. (2010) Regulation of amyloid precursor protein processingby the Beclin 1 complex. PLoS One, 5, e11102.
74. Wong,E.S., Tan, J.M., Soong, W.E., Hussein, K., Nukina, N., Dawson, V.L., Dawson, T.M., Cuervo, A.M. and Lim, K.L. (2008) Autophagy-mediatedclearance of aggresomes is not a universal phenomenon. Hum. Mol. Genet., 17, 2570-2582.
75. Spencer, B., Potkar, R., Trejo, M., Rockenstein, E., Patrick, C., Gindi, R., Adame, A., Wyss-Coray, T. and Masliah, E. (2009) Beclin 1 gene transferactivates autophagy and ameliorates the neurodegenerative pathology inalpha-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci., 29, 13578-13588.
76. Palmisano, R., Golfi, P., Heimann, P., Shaw, C., Troakes, C., Schmitt-John, T. and Bartsch, J.W. (2011) Endosomal accumulation of APP in wobblermotor neurons reflects impaired vesicle trafficking: implications for humanmotor neuron disease. BMC Neurosci., 12, 24.
77. Vitner, E.B., Dekel, H., Zigdon, H., Shachar, T., Farfel-Becker, T., Eilam, R., Karlsson, S. and Futerman, A.H. (2010) Altered expression anddistribution of cathepsins in neuronopathic forms of Gaucher disease and inother sphingolipidoses. Hum. Mol. Genet., 19, 3583-3590.
78. Zha, Q., Ruan, Y., Hartmann, T., Beyreuther, K. and Zhang, D. (2004) GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol. Psychiatry, 9, 946-952.
79. Keilani, S., Lun, Y., Stevens, A.C., Williams, H.N., Sjoberg, E.R., Khanna, R., Valenzano, K.J., Checler, F., Buxbaum, J.D., Yanagisawa, K. et al. (2012) Lysosomaldysfunction in a mousemodel of Sandhoff disease leads toaccumulation of ganglioside-bound amyloid-beta peptide. J. Neurosci., 32, 5223-5236.
80. Boland, B., Smith, D.A., Mooney, D., Jung, S.S., Walsh, D.M. and Platt, F.M. (2010) Macroautophagy is not directly involved in the metabolism ofamyloid precursor protein. J. Biol. Chem., 285, 37415-37426.
81. Saito, Y., Suzuki, K., Hulette, C.M. and Murayama, S. (2004) Aberrantphosphorylation of alpha-synuclein in human Niemann-Pick type C1 disease. J. Neuropathol. Exp. Neurol., 63, 323-328.
82. Jeyakumar, M., Dwek, R.A., Butters, T.D. and Platt, F.M. (2005) Storagesolutions: treating lysosomal disorders of the brain. Nat. Rev. Neurosci., 6, 713-725.
83. Tamboli, I.Y., Prager, K., Barth, E., Heneka, M., Sandhoff, K. and Walter, J. (2005) Inhibition of glycosphingolipid biosynthesis reduces secretion of thebeta-amyloid precursor protein and amyloid beta-peptide. J. Biol. Chem., 280, 28110-28117.
84. Yahi, N., Aulas, A. and Fantini, J. (2010) How cholesterol constrainsglycolipid conformation for optimal recognition of Alzheimer's betaamyloid peptide (Abeta1-40). PLoS One, 5, e9079.
85. Brewer, G.J. and Torricelli, J.R. (2007) Isolation and culture of adult neuronsand neurospheres. Nat. Protoc., 2, 1490-1498.
86. Nojima, K., Ando, K., Fujiwara, H. and Ando, S. (2000) Effects of carbonions on primary cultures of mouse brain cells. Adv. Space Res., 25, 2051-2056.
87. Facci, L. and Skaper, S.D. (2012) Culture of rodent cortical and hippocampalneurons. Methods Mol. Biol., 846, 49-56.
88. Paxinos, G. and Franklin, K.B.J. The Mouse Brain in StereotaxicCoordinates. San Diego: Academic Press, 2001.
89. Grabowski, G.A., Osiecki-Newman, K., Dinur, T., Fabbro, D., Legler, G., Gatt, S. and Desnick, R.J. (1986) Human acid beta-glucosidase. Use ofconduritol B epoxide derivatives to investigate the catalytically activenormal and Gaucher disease enzymes. J. Biol. Chem., 261, 8263-8269.
90. Hornig-Do, H.T., Gunther, G., Bust, M., Lehnartz, P., Bosio, A. and Wiesner, R.J. (2009) Isolation of functional pure mitochondria by superparamagneticmicrobeads. Anal. Biochem., 389, 1-5.
91. Higashi, T., Isomoto, A., Tyuma, I., Kakishita, E., Uomoto,M.and Nagai, K. (1985) Quantitative and continuous analysis of ATP release from bloodplatelets with firefly luciferase luminescence. Thromb.Haemost., 53, 65-69.
92. Manfredi, G., Yang, L., Gajewski, C.D. and Mattiazzi, M. (2002) Measurements of ATP in mammalian cells. Methods, 26, 317-326.
93. Crouch, S.P., Kozlowski, R., Slater, K.J. and Fletcher, J. (1993) The use ofATP bioluminescence as a measure of cell proliferation and cytotoxicity. J. Immunol. Methods, 160, 81-88.
94. Stanley, P.E. (1986) Extraction of adenosine triphosphate from microbialand somatic cells. Methods Enzymol., 133, 14-22.
95. Li, R. and Guan,M.X.(2010) Humanmitochondrial leucyl-tRNA synthetasecorrects mitochondrial dysfunctions due to the tRNALeu(UUR) A3243Gmutation, associated with mitochondrial encephalomyopathy, lacticacidosis, and stroke-like symptoms and diabetes. Mol. Cell Biol., 30, 2147-2154.